Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.

Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Abstract Text:

    anna marie mulliganAnna Marie Mulligan,frances p o'malleyFrances P O'malley,marguerite ennisMarguerite Ennis,i george fantusI George Fantus,pamela j goodwinPamela J Goodwin,anna marie mulliganAnna Marie Mulligan,frances p o'malleyFrances P O'Malley,marguerite ennisMarguerite Ennis,i george fantusI George Fantus,pamela j goodwinPamela J Goodwin,anna marie mulliganAnna Marie Mulligan,frances p o'malleyFrances P O'Malley,marguerite ennisMarguerite Ennis,i george fantusI George Fantus,pamela j goodwinPamela J Goodwin,

    Fasting insulin is related to outcome in early breast cancer. We evaluated the expression of insulin receptor (IR) and its prognostic significance in patients with early stage breast cancer. Tumors from 191 patients with T1-3, N0-1, M0 breast cancer who were enrolled at a single center of a multicenter cohort study were used to construct microarrays with subsequent immunohistochemical evaluation of IR, IGF-IR, ER, PgR and HER2/neu. Correlation of biomarker expression with traditional prognostic factors, serum biochemistry (notably insulin) and clinical outcome was assessed. IR was strongly positive (Allred score = 8) in 54% of tumors. High IR expression significantly correlated with favorable prognostic markers (low tumor grade, lymph node negativity and progesterone receptor positivity) but not with fasting levels of circulating insulin. At a median follow-up of 9.1 years, high vs. low IR expression (an Allred score of 8 vs. 0-7) was associated with statistically significant improved distant disease-free survival (multivariate hazard ratio (HR) = 0.4; P = 0.027) and overall survival (multivariate HR = 0.26; P = 0.005). IR is highly expressed in the majority of early stage breast cancers but this expression is not clearly down-regulated in the presence of high insulin levels. Furthermore, high expression of IR is independently and significantly associated with more favorable clinical outcomes. Follow-up intervention research is recommended.

    Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Publishing Authors By Initials

    am mulliganAM Mulligan,fp o'malleyFP O'malley,m ennisM Ennis,ig fantusIG Fantus,pj goodwinPJ Goodwin,am mulliganAM Mulligan,fp o'malleyFP O'Malley,m ennisM Ennis,ig fantusIG Fantus,pj goodwinPJ Goodwin,am mulliganAM Mulligan,fp o'malleyFP O'Malley,m ennisM Ennis,ig fantusIG Fantus,pj goodwinPJ Goodwin,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Breast cancer research and treatment

    VOLUME: 106

    Page Numbers: 39-47

    Journal Abbreviation: Breast Cancer Res. Treat.

    ISSN: 0167-6806

    DAY: 13

    MONTH: 01

    YEAR: 2007

    Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8111104

    Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.

    AFFILIATION: Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada.

    Country: Netherlands

    Netherlands Research PublicationNetherlands Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Breast Cancer Res Treat

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News